Validated predictive model for treatment and prognosis of adrenocortical carcinoma

被引:1
作者
Zuber, Samuel M. [1 ,2 ]
Kuchta, Kristine [3 ]
Holoubek, Simon A. [4 ]
Khokar, Amna [5 ]
Moo-Young, Tricia [1 ,2 ]
Prinz, Richard A. [1 ,2 ]
Winchester, David J. [6 ]
机构
[1] NorthShore Univ Hlth Syst, Dept Surg, 2650 Ridge Ave,Walgreen Suite 2507, Evanston, IL 60201 USA
[2] Univ Chicago Med, Dept Surg, Chicago, IL USA
[3] NorthShore Univ Hlth, Bioinformat & Res Core, Evanston, IL USA
[4] Univ Wisconsin, Sch Med & Publ Hlth, Div Endocrine Surg, Madison, WI USA
[5] John H Stroger Jr Cook Cty Hosp, Dept Surg, Chicago, IL USA
[6] City Hope Natl Med Ctr, Dept Surg, Zion, IL USA
关键词
SURVIVAL; MITOTANE; CISPLATIN; CANCER; DOXORUBICIN; MANAGEMENT; RECURRENCE; ETOPOSIDE; NOMOGRAMS; RESECTION;
D O I
10.1016/j.surg.2023.08.047
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Adrenocortical carcinoma has a poor prognosis and multiple clinical, pathological, and treatment variables. Currently, we lack a prognostic and treatment calculator to determine the survival and efficacy of adjuvant chemoradiation. We aimed to validate a calculator to assess prognosis and treatment. Methods: We searched the National Cancer Database to identify patients with adrenocortical carcinoma surgically treated from 2004 to 2020 and randomly allocated them into a training (80%) or validation set (20%). We analyzed the variables of age; sex; Charlson Comorbidity Index; insurance status; tumor size; pathologic tumor, node, and metastasis categories; surgical margins; and use of chemotherapy and radiation therapy. We used Cox regression prediction models and bootstrap coefficients to generate a mathematical model to predict 5- and 10 -year overall survival. After using the area under the curve analysis to assess the model's performance, we compared overall survival in the training and validation sets. Results: Multivariable analysis of the 3,480 patients included in the study revealed that all variables were significant except sex (P <.05) and incorporated into a mathematical model. The area under the curve for 5- and 10 -year overall survival was 0.68 and 0.70, respectively, for the training set and 0.70 and 0.72, respectively, for the validation set. For the bootstrap coefficients, the 5- and 10 -year overall survival was 6.4% and 4.1%, respectively, above the observed mean. Conclusion: Our model predicts the overall survival of patients with adrenocortical carcinoma based on clinical, pathologic, and treatment variables and can assist in individualizing treatment. (c) 2023 Elsevier Inc. All rights reserved.
引用
收藏
页码:743 / 751
页数:9
相关论文
共 35 条
  • [1] Clinical review: Adrenocortical carcinoma: Clinical update
    Allolio, Bruno
    Fassnacht, Martin
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (06) : 2027 - 2037
  • [2] American Cancer Society, Survival rates for adrenal cancer
  • [3] Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial
    Berruti, A
    Terzolo, M
    Sperone, P
    Pia, A
    Della Casa, S
    Gross, DJ
    Carnaghi, C
    Casali, P
    Porpiglia, F
    Mantero, F
    Reimondo, G
    Angeli, A
    Dogliotti, L
    [J]. ENDOCRINE-RELATED CANCER, 2005, 12 (03) : 657 - 666
  • [4] Adrenocortical Carcinoma in the United States Treatment Utilization and Prognostic Factors
    Bilimoria, Karl Y.
    Shen, Wen T.
    Elaraj, Dina
    Bentrern, David J.
    Winchester, David J.
    Kebebew, Electron
    Sturgeon, Cord
    [J]. CANCER, 2008, 113 (11) : 3130 - 3136
  • [5] Using the National Cancer Database for Outcomes Research
    Boffa, Daniel J.
    Rosen, Joshua E.
    Mallin, Katherine
    Loomis, Ashley
    Gay, Greer
    Palis, Bryan
    Thoburn, Kathleen
    Gress, Donna
    McKellar, Daniel P.
    Shulman, Lawrence N.
    Facktor, Matthew A.
    Winchester, David P.
    [J]. JAMA ONCOLOGY, 2017, 3 (12) : 1722 - 1728
  • [6] Practical Application of a Calculator for Conditional Survival in Colon Cancer
    Chang, George J.
    Hu, Chung-Yuan
    Eng, Cathy
    Skibber, John M.
    Rodriguez-Bigas, Miguel A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) : 5938 - 5943
  • [7] S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study
    Elhassan, Y. S.
    Altieri, B.
    Berhane, S.
    Cosentini, D.
    Calabrese, A.
    Haissaguerre, M.
    Kastelan, D.
    Fragoso, M. C. B., V
    Bertherat, J.
    Al Ghuzlan, A.
    Haak, H.
    Boudina, M.
    Canu, L.
    Loli, P.
    Sherlock, M.
    Kimpel, O.
    Lagana, M.
    Sitch, A. J.
    Kroiss, M.
    Arlt, W.
    Terzolo, M.
    Berruti, A.
    Deeks, J. J.
    Libe, R.
    Fassnacht, M.
    Ronchi, C. L.
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2022, 186 (01) : 25 - 36
  • [8] Adrenocortical Carcinoma
    Else, Tobias
    Kim, Alex C.
    Sabolch, Aaron
    Raymond, Victoria M.
    Kandathil, Asha
    Caoili, Elaine M.
    Jolly, Shruti
    Miller, Barbra S.
    Giordano, Thomas J.
    Hammer, Gary D.
    [J]. ENDOCRINE REVIEWS, 2014, 35 (02) : 282 - 326
  • [9] Adjuvant Therapies and Patient and Tumor Characteristics Associated With Survival of Adult Patients With Adrenocortical Carcinoma
    Else, Tobias
    Williams, Andrew R.
    Sabolch, Aaron
    Jolly, Shruti
    Miller, Barbra S.
    Hammer, Gary D.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (02) : 455 - 461
  • [10] Development and Internal Validation of a Multivariable Prediction Model for Adrenocortical-Carcinoma-Specific Mortality
    Ettaieb, Madeleine H. T.
    van Kuijk, Sander M. J.
    de Wit-Pastoors, Annelies
    Feelders, Richard A.
    Corssmit, Eleonora P. M.
    Eekhoff, Elisabeth M. W.
    van der Valk, Paul
    Timmers, Henri J. L. M.
    Kerstens, Michiel N.
    Klumpen, Heinz-Josef
    van Leeuwaarde, Rachel S.
    Havekes, Bas
    Haak, Harm R.
    [J]. CANCERS, 2020, 12 (09) : 1 - 16